Welcome to our dedicated page for CTT PHARMACEUTICAL HOLDINGS SEC filings (Ticker: CTTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CTT PHARMACEUTICAL HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CTT PHARMACEUTICAL HOLDINGS's regulatory disclosures and financial reporting.
CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) reported that it purchased 3,000 shares of its CTTH security on September 2, 2026, in a non-derivative open market or private transaction at a price of $0.0489 per share. Following this purchase, the reporting holder directly owns 9,387,256 shares.
No Rule 10b5-1 trading plan is reported for this transaction.
CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) reported that its CEO purchased shares of the company’s common stock. On 2026-08-31, the reporting person bought 3,500 shares of CTTH in a purchase described as an open market or private transaction at $0.049 per share, bringing the reported direct holdings to 9,384,256 shares.
CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH), as reporting person, disclosed a purchase of its CTTH common stock. On 2026-08-24, it purchased 2,100 shares at a price of $0.055 per share in an open market or private transaction, bringing the reported directly held position to 9,360,756 shares after the transaction.
CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) reported an insider purchase of its own common stock. On 2026-08-20, the reporting person acquired 11,500 shares of CTTH in an open market or private transaction at $0.045 per share, resulting in 9,378,656 shares held directly after the transaction.
CTT Pharmaceutical Holdings, Inc. (CTTH) reported an insider purchase of its common stock. The reporting person, listed as CTT Pharmaceutical Holdings, Inc. in its capacity as CEO, purchased 10,000 CTTH shares on 2026-08-19 at $0.059 per share in an open-market or private transaction. Following this transaction, the filing reports 9,365,456 shares of CTTH common stock held with direct ownership.
CTT Pharmaceutical Holdings, Inc. (CTTH), reporting as CEO, purchased 1,800 shares of its common stock on 2026-08-14 in an open-market or private transaction at $0.062 per share. Following this transaction, the reporting holder directly owns 9,355,456 shares of CTTH.
CTT Pharmaceutical Holdings, Inc. reports that the U.S. Patent and Trademark Office has approved a continuation-in-part patent for its micelle-based delivery technology, effective August 11, 2026. The patent adds protection for formulations delivering nicotine, vitamins, and caffeine and supports multiple dosage forms, including dissolvable strips, gum, pouches, lozenges, and dissolving tablets. The company describes this as part of its strategy to strengthen its patent portfolio around oral drug delivery systems designed for rapid onset, patient convenience, and efficient absorption across pharmaceutical, therapeutic, and nutraceutical markets.
CTT Pharmaceutical Holdings, Inc. reported that its CEO purchased 7,700 CTTH shares on August 7, 2026 in a non-derivative open market or private transaction at $0.065 per share. Following this purchase, the CEO directly owns 9,353,656 shares of CTTH. The transaction was not marked as pursuant to a Rule 10b5-1 trading plan.
CTT Pharmaceutical Holdings, Inc. is registering up to 6,250,000 shares of common stock for resale by RH2 Equity Partners under an equity line of credit. These are secondary sales by the investor; the company will not receive cash from resales of these shares.
The equity line allows CTT to sell up to $10,000,000 of stock to RH2 at 85% of the lowest daily VWAP over 10 trading days, subject to a 4.99% beneficial ownership cap. Common shares outstanding were 59,722,232, and would be 65,972,232 if all 6,250,000 shares are issued. Management currently plans to draw no more than $1,000,000 under the facility unless the share price exceeds $1.00, aiming to limit dilution.
The company develops patented fast-dissolving oral strips for drugs, nutraceuticals and nicotine, and plans to prioritize approximately $500,000 of equity-line proceeds for in house manufacturing equipment and related scale-up, focusing first on nicotine and vitamin products. CTT is a development-stage business with no recent revenues, reported net losses of $250,229 in 2024 and $155,907 in 2025, minimal cash of $7,089 as of March 31, 2026, and an auditor going concern qualification, and highlights significant regulatory, financing, volatility and dilution risks.